Basal forebrain parvalbumin neuron dysfunction links network oscillation deficits to hippocampal pathology in Alzheimer’s disease
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background Basal forebrain (BF) degeneration is a key pathological feature of Alzheimer’s disease (AD) and is closely associated with cognitive decline. Although parvalbumin (PV)-expressing neurons are abundant in the BF and are important regulators of cortical network activity, their contribution to AD pathogenesis remains poorly understood. Methods To investigate the role of BF-PV neurons in AD, we examined the effects of PV knockdown in the BF of APP/PS1 mice. Electrophysiological recordings, behavioral analyses, retrograde tracing, hippocampal transcriptome profiling, and integrative computational analyses, including meta-correlation analysis and artificial neural network (ANN) modeling, were performed to assess the impact of BF-PV loss on neural network activity, hippocampal pathology, and cognitive function. Results BF-PV knockdown disrupted theta oscillations and theta–gamma coupling in the parietal cortex and impaired hippocampal synaptic activity and memory-related behaviors in mice. Retrograde tracing demonstrated that BF neuronal circuits project directly to the hippocampus. Transcriptome analysis revealed that BF-PV knockdown increased amyloidosis- and microvessel-associated gene signatures while reducing synaptic plasticity–related gene expression in the hippocampus. Furthermore, meta-correlation analyses and ANN modeling indicated that BF-PV dysfunction strongly predicts hippocampal pathology, disrupted EEG coupling, and behavioral abnormalities in AD mice. Conclusions These findings identify BF-PV neuronal dysfunction as an important contributor to hippocampal pathology, neural network dysregulation, and cognitive impairment in AD, highlighting BF-PV neurons as a potential mechanistic link between BF degeneration and AD progression.